These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30109845)

  • 21. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis.
    Kane JM; Zhao C; Johnson BR; Baker RA; Eramo A; McQuade RD; Duca AR; Sanchez R; Peters-Strickland T
    J Med Econ; 2015 Feb; 18(2):145-54. PubMed ID: 25347448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
    Turncliff R; Hard M; Du Y; Risinger R; Ehrich EW
    Schizophr Res; 2014 Nov; 159(2-3):404-10. PubMed ID: 25266547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia.
    Jain R; Meyer J; Wehr A; Rege B; von Moltke L; Weiden PJ
    CNS Spectr; 2020 Jun; 25(3):323-330. PubMed ID: 31111801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
    Aggarwal A; Gopalakrishna G; Lauriello J
    Clin Schizophr Relat Psychoses; 2016; 10(1):58-63. PubMed ID: 27074333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study.
    Miller BJ; Claxton A; Du Y; Weiden PJ; Potkin SG
    Schizophr Res; 2019 Jun; 208():44-48. PubMed ID: 30745067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia.
    Hard ML; Wehr AY; Du Y; Weiden PJ; Walling D; von Moltke L
    J Clin Psychopharmacol; 2018 Oct; 38(5):435-441. PubMed ID: 30015676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
    Citrome L; Du Y; Risinger R; Stankovic S; Claxton A; Zummo J; Bose A; Silverman BL; Ehrich EW
    Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia.
    Fleischhacker WW; Sanchez R; Johnson B; Jin N; Forbes RA; McQuade R; Baker RA; Carson W; Kane JM
    Int Clin Psychopharmacol; 2013 Jul; 28(4):171-6. PubMed ID: 23615694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
    Marder SR; McQuade RD; Stock E; Kaplita S; Marcus R; Safferman AZ; Saha A; Ali M; Iwamoto T
    Schizophr Res; 2003 Jun; 61(2-3):123-36. PubMed ID: 12729864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
    Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
    J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
    Potkin SG; Preda A
    Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia.
    McEvoy JP; Risinger R; Mykhnyak S; Du Y; Liu CC; Stanford AD; Weiden PJ
    J Clin Psychiatry; 2017; 78(8):1103-1109. PubMed ID: 28937706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
    Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
    Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.
    Casey DE; Carson WH; Saha AR; Liebeskind A; Ali MW; Jody D; Ingenito GG;
    Psychopharmacology (Berl); 2003 Apr; 166(4):391-9. PubMed ID: 12610718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A safety evaluation of aripiprazole in the treatment of schizophrenia.
    Preda A; Shapiro BB
    Expert Opin Drug Saf; 2020 Dec; 19(12):1529-1538. PubMed ID: 33064050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.
    Correll CU; Kohegyi E; Zhao C; Baker RA; McQuade R; Salzman PM; Sanchez R; Nyilas M; Carson W
    J Am Acad Child Adolesc Psychiatry; 2017 Sep; 56(9):784-792. PubMed ID: 28838583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.
    Durgam S; Greenberg WM; Li D; Lu K; Laszlovszky I; Nemeth G; Migliore R; Volk S
    Psychopharmacology (Berl); 2017 Jan; 234(2):199-209. PubMed ID: 27807604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initiation of Aripiprazole Lauroxil Long-Acting Injectable in Adolescents During Hospitalization: A Case Series.
    Moon E; Kim E; Williams A
    J Child Adolesc Psychopharmacol; 2023 Dec; 33(10):433-438. PubMed ID: 37910863
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.